Mometasone furoate nasal spray increases the number of minimal-symptom days in patients with acute rhinosinusitis

MFNS 200 μg twice daily significantly increased minimal-symptom days vs amoxicillin or placebo in patients with ARS. Results of this intranasal corticosteroids (INS) therapy indicate it can improve outcomes and potentially reduce inappropriate antibiotic use.